Place of Glycation in Diabetic Retinopathy

Sponsor
Mohammed VI University Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05364723
Collaborator
(none)
1,000
36

Study Details

Study Description

Brief Summary

  1. Definition: Diabetic retinopathy is a microangiopathic complication of diabetes diabetes mellitus. Its pathophysiology includes glycation and intracellular hypoxia. Diabetic retinopathy (DR) is a microvascular complication of diabetes. It is the leading cause of It is the leading cause of blindness and visual impairment in people under the age of 60 in industrialized countries.

Chronic hyperglycemia during diabetes plays a major role in the occurrence of diabetic diabetic retinopathy by promoting protein glycation and the accumulation of glycation end products (GTPs). GTPs are a heterogeneous group of compounds resulting from non-enzymatic and irreversible reactions between reducing sugars and amine groups of biological molecules such as proteins, lipids or nucleic acids.

  1. Interest: The aim of our work is to describe the mechanisms by which glycation participates in the pathophysiology of diabetic retinopathy and to discuss the use of AGEs as biomarkers in this biomarkers in this pathological context and the therapeutic means that limit the toxicity of of AGEs.

The study is designed through a retrospective and prospective observational study to establish the of glycation in the occurrence of diabetic retinopathy. It will describe the demographic demographic profiles, glycemic control, clinical and paraclinical status of patients with diabetic diabetic retinopathy and will evaluate the relationship between glycation and diabetic retinopathy as well as the factors that influence this glycation in these patients, and induce the occurrence and / or of diabetic retinopathy. The data collected will allow to improve the knowledge, the diagnosis and the treatment of diabetic diabetic retinopathy, as well as a good management of the patients who should benefit from a more individualized and individualized and adequate treatment.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    1000 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Other
    Official Title:
    Place of Glycation in Diabetic Retinopathy
    Anticipated Study Start Date :
    May 15, 2022
    Anticipated Primary Completion Date :
    May 15, 2025
    Anticipated Study Completion Date :
    May 15, 2025

    Outcome Measures

    Primary Outcome Measures

    1. distribution of diabetic retinopathy in eastern morocco [1year]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    • Diabetic patients type 1 and type 2, of both sexes, and of all ages. Regular follow-up
    Exclusion Criteria:
    • Other types of diabetes. Irregular follow-up.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Mohammed VI University Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Oujidi Wissale, ophthalmology resident, Mohammed VI University Hospital
    ClinicalTrials.gov Identifier:
    NCT05364723
    Other Study ID Numbers:
    • MohammedVIUHophtalmology
    First Posted:
    May 6, 2022
    Last Update Posted:
    May 6, 2022
    Last Verified:
    May 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Oujidi Wissale, ophthalmology resident, Mohammed VI University Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 6, 2022